Teva granted pretrial appeal in high-stakes Copaxone kickbacks case

Teva’s latest play in its yearslong defense against kickback claims levied by the U.S. government has secured the company a slight legal reprieve.

In granting a pretrial appeal, the U.S. Court of Appeals for the First Circuit has agreed to look at one aspect of the case—the level of causation tied to alleged false claims filings to Medicare—before the sides take their arguments to trial.